The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Abdel Latif, Ghada A ^a   Al Abd, Ahmed M ^b,c   Tadros, Mariane G ^a   Al Abbasi, Fahad A ^b   Khalifa, Amany E ^a,d   Abdel Naim, Ashraf B ^a  

^a Ain Shams University   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d CHILDREN S CANCER HOSPITAL   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

3,4-DIHYDROXYBENZOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXAMIC ACID; RESVERATROL; STILBENE DERIVATIVE; TRASTUZUMAB;

APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; FEMALE; GENETICS; HUMAN; IC50; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; RECEPTOR, ERBB-2; STILBENES; TRASTUZUMAB;

EID: 84937020208     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12054     Document Type: Article

References (49)

1. Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC genomics 7, 96, doi: 10.1186/1471-2164-7-96 (2006).
2. Zhou, B. P. HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-kappa B Pathway. Journal of Biological Chemistry 275, 8027-8031, doi: 10.1074/jbc.275.11.8027 (2000).
3. Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal 19, 3159-3167, doi: 10.1093/emboj/19.13.3159 (2000).
4. Hynes, N. E. & Stern, D. F. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochimica et biophysica acta 1198, 165-184 (1994).
5. Carlomagno, C. et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 14, 2702-2708 (1996).
6. Schlessinger, J. Common and distinct elements in cellular signaling via EGF and FGF receptor. Science 306, 1506-1507 (2004).
7. Cobleigh, M. A. et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. Journal of Clinical Oncology 17, 2639 (1999).
8. Vogel, C. L. et al. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology 20, 719-726, doi: 10.1200/jco.20.3.719 (2002).
9. Jang, M. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220 (1997).
10. Miki, H. et al. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. International journal of oncology 40, 1020-1028, doi: 10.3892/ijo.2012.1325 (2012).
11. Filomeni, G., Graziani, I., Rotilio, G. & Ciriolo, M. R. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes & nutrition 2, 295-305, doi: 10.1007/s12263-007-0059-9 (2007).
12. Ge, J. et al. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomedical and environmental sciences : BES 26, 902-911, doi: 10.3967/bes2013.019 (2013).
13. Chen, Q., Ganapathy, S., Singh, K. P., Shankar, S. & Srivastava, R. K. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PloS one 5, e15288, doi: 10.1371/journal.pone.0015288 (2010).
14. Al-Abd, A. M. et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell proliferation 44, 591-601, doi: 10.1111/j.1365-2184.2011.00783.x (2011).
15. Inayat, M. S., Chendil, D., Mohiuddin, M. & al., e. Didox ( a novel ribonucleotide reductase inhibitor) overcomes bcl-2 mediated radiation resistance in prostate cancer cell ; PC3. Cancer biology and therapy 1, 539-545 (2002).
16. Al-Abd, A. M., Al-Abbasi, F. A., Asaad, G. F. & Abdel-Naim, A. B. Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. European journal of pharmacology 718, 361-369, doi: 10.1016/j.ejphar.2013.08.009 (2013).
17. Raje, N. et al. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. British journal of haematology 135, 52-61, doi: 10.1111/j.1365-2141.2006.06261.x (2006).
18. Wakisaka, N., Yoshizaki, T., Raab-Traub, N. & Pagano, J. S. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. International journal of cancer. Journal international du cancer 116, 640-645, doi: 10.1002/ijc.21096 (2005).
19. Perez, E. A. et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 4307-4315, doi: 10.1200/JCO.2009.26.2154 (2010).
20. Slamon, D. et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine 365, 1273-1283, doi: 10.1056/NEJMoa0910383 (2011).
21. Cragg, G. M., Grothaus, P. G. & Newman, D. J. Impact of natural products on developing new anti-cancer agents. Chemical reviews 109, 3012-3043, doi: 10.1021/cr900019j (2009).
22. Eisenberg, D. M. et al. Developing a library ofauthenticated Traditional Chinese medicinal (TCM) plants for systematic biological evaluation-rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 82, 17-33 (2011).
23. Bai, Z. & Gust, R. Breast cancer, estrogen receptor and ligands. Archiv der Pharmazie 342, 133-149, doi: 10.1002/ardp.200800174 (2009).
24. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
25. Hudis, C. A. Trastuzumab - Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine 357, 39-51, doi: 10.1056/NEJMra043186 (2007).
26. Untch, M. et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of Oncology 19, 1090-1096, doi: 10.1093/annonc/mdn005 (2008).
27. Miura, D., Yoneyama, K., Furuhata, Y. & Shimizu, K. Paclitaxel Enhances Antibody-dependent Cell-mediated Cytotoxicity of Trastuzumab by Rapid Recruitment of Natural Killer Cells in HER2-positive Breast Cancer. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 81, 211-220 (2014).
28. Nagayama, A. et al. Comparative Effectiveness of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta- Analysis. Journal of the National Cancer Institute 106, doi: 10.1093/jnci/dju203 (2014).
29. Fukui, M., Yamabe, N. & Zhu, B. T. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. European journal of cancer 46, 1882-1891, doi: 10.1016/j.ejca.2010.02.004 (2010).
30. Jazirehi, A. R. & Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular cancer therapeutics 3, 71-84 (2004).
31. He, X., Wang, Y., Zhu, J., Orloff, M. & Eng, C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer letters 301, 168-176, doi: 10.1016/j.canlet.2010.11.012 (2011).
32. Milella, M. et al. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 7747-7756, doi: 10.1158/1078-0432.CCR-04-0908 (2004).
33. Shukla, Y. & Singh, R. Resveratrol and cellular mechanisms of cancer prevention. Annals of the New York Academy of Sciences 1215, 1-8, doi: 10.1111/j.1749-6632.2010.05870.x (2011).
34. Kim, J. A. et al. HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. International journal of oncology 44, 473-480, doi: 10.3892/ijo.2013.2207 (2014).
35. Chen, X., Wang, H., Ou-Yang, X. N., Xie, F. W. & Wu, J. J. Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway. Contemporary oncology 17, 363-369, doi: 10.5114/wo.2013.35292 (2013).
36. Hommelgaard, A. M., Lerdrup, M. & van Deurs, B. Association with membrane protrusions makes ErbB2 an internalizationresistant receptor. Molecular biology of the cell 15, 1557-1567, doi: 10.1091/mbc.E03-08-0596 (2004).
37. Cuello, M. et al. Down-regulation of the ErbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ErbB-2. Cancer research 61, 4892-4900 (2001).
38. Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y. & Sela, M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America 106, 3294-3299, doi: 10.1073/pnas.0812059106 (2009).
39. Provinciali, M. et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International journal of cancer. Journal international du cancer 115, 36-45, doi: 10.1002/ijc.20874 (2005).
40. Wicha, M. S., Liu, S. & Dontu, G. Cancer Stem Cells: An Old Idea-A Paradigm Shift. Cancer research 66, 1883-1890, doi: 10.1158/0008-5472.CAN-05-3153 (2006).
41. Ithimakin, S. et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer research 73, 1635-1646, doi: 10.1158/0008-5472.CAN-12-3349 (2013).
42. Menendez, J. A., Vellon, L., Colomer, R. & Lupu, R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (ErbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Annals of oncology : official journal of the European Society for Medical Oncology /ESMO 16, 359-371, doi: 10.1093/annonc/mdi090 (2005).
43. Janicke, R. U., Sprengart, M. L., Wati, M. R. & Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. The Journal of biological chemistry 273, 9357-9360 (1998).
44. Bhardwaj, A. et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109, 2293-2302, doi: 10.1182/blood-2006-02-003988 (2007).
45. Singh, N., Zaidi, D., Shyam, H., Sharma, R. & Balapure, A. K. Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman. PloS one 7, e37736, doi: 10.1371/journal.pone.0037736 (2012).
46. Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute 82, 1107-1112 (1990).
47. Mahmoud, A. M., Al-Abd, A. M., Lightfoot, D. A. & El-Shemy, H. A. Anti-cancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent. Journal of Enzyme Inhibition and Medicinal Chemistry 27, 673-679, doi: 10.3109/14756366.2011.607446 (2012).
48. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 22, 27-55 (1984).
49. Longo, M. C., Berninger, M. S. & Hartley, J. L. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 93, 125-128 (1990).